Antiparkinsonian agents: Clinically significant drug interactions and adverse effects, and their management

CNS Drugs

Volumn 9, Issue 4, 1998, Pages 291-310

  Dalvi, Arif ^a   Ford, Blair ^a,b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; COTRIMOXAZOLE; CYCLOPENTHIAZIDE; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROCHLOROTHIAZIDE; LEVODOPA; LISURIDE; LOXAPINE; MOLINDONE; MONOAMINE OXIDASE INHIBITOR; NITROPRUSSIDE SODIUM; PERGOLIDE; PHENOTHIAZINE DERIVATIVE; PHYSOSTIGMINE; PRAMIPEXOLE; PYRIDOXINE; RESERPINE; RISPERIDONE; ROPINIROLE; SELEGILINE; TETRABENAZINE; TIOTIXENE; UNINDEXED DRUG;

ARTICLE; DELIRIUM; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG OVERDOSE; DRUG POTENTIATION; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; LIVEDO RETICULARIS; MENTAL DISEASE; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROTONIN SYNDROME;

EID: 0031917997     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809040-00005     Document Type: Article

References (131)

1. Schoenberg BS. Epidemiology of movement disorders. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworths, 1987: 17-32
2. Stockton P, Jones JK. Medication use by the elderly. Aging Clin Exp Res 1993; 5 (5): 337-47
3. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211-4
4. Pfeiffer RF. Antiparkinsonian agents: drug interactions of clinical significance. Drug Saf 1996; 14 (5): 343-54
5. Charcot J-M. Lectures on the disease of the nervous system. London: New Sydenham Society, 1877
6. Cotzias GC, van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-9
7. Tune L, Carr S, Hong E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4
8. Algeri S, Cerletti C, Curcio M, et al. Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man. Eur J Pharmacol 1976; 35: 293-9
9. Roberts J, Waller DG, von Renwick AG, et al. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Br J Clin Pharmacol 1996; 41: 331-7
10. Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. Absorption and metabolism of L-dopa by the human stomach. Eur J Clin Invest 1971; 1: 313-20
11. Gianutsos G, Chute S, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long term administration of amantadine. Eur J Pharmacol 1985; 110: 357-61
12. Nastuck WC, Su PC, Doublet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264: 76-9
13. Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol 1992; 94 Suppl.: S4-6
14. Pfeiffer RF. Amantadine-induced vocal myoclonus [letter]. Mov Disord 1996; 11 (1): 104-51
15. Bleidner WE, Harman JB, Hewes WE, et al. Absorption, distribution, and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 1965; 150: 484-90
16. Speeg KV, Leighton JA, Maldonoado AL. Case report: toxic delirium in a patient taking amantadine and trimethopim-sulfamethoxazole. Am J Med Sci 1989; 298: 410-2
17. Wilson TW, Rajput AH. Amantadine-dyazide interaction. Can Med Assoc J 1983; 129: 974-5
18. Kulig K, Moore LL, Kirk M, et al. Bromocriptine-associated headache: possible life-threatening sympathomimetic reaction. Obst Gynecol 1991; 78: 941-3
19. Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine in normal subjects [abstract]. Clin Pharmacol Ther 1990; 47: 166
20. Sibley WA, Laguna JF. Enhancement of bromocriptine clinical effect and plasma levels with erythromycin. Excerpta Med 1981; 548: 329-30
21. Ayres J, Maseley MN. Alcohol increases bromocriptine side effects [letter]. N Engl J Med 1980; 302: 806
22. Schwinn G, Dirks H, McIntosh C, et al. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months. Eur J Clin Invest 1977; 7: 101-7
23. Andersen PK, Christensen KN, Hole P, et al. Sodium nitroprusside and epidural blockade to treat severe ergotism. N Engl J Med 1977; 296: 1271-3
24. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990; 39: 491-506
25. Piercey ME, Walker EL, Feldpausch DL, et al. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Let 1996; 219: 138-40
26. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease. Neurology 1997; 49: 162-8
27. Pharmacia and Upjohn Co. Mirapex package insert. Kalamazoo (MI): Pharmacia and Upjohn Co., Jun 1997
28. SmithKline Beecham. Requip package insert. Crawley. UK: SmithKline Beecham, Sep 1997
29. Adler CH, Sethi KD, Davis TL, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49: 393-9
30. Data on file, SmithKline Beecham
31. Kreider MS, Knox S, Gardiner D, et al. A multicenter double blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [abstract]. Neurology 1996; 46: A475
32. Duvoisin RC, Yahr MD, Cote LD. Pyridoxine reversal of L-dopa effects in parkinsonism [letter]. Trans Am Neurol Ass 1969; 94: 81
33. Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-8
34. Juncos JJ. Levodopa: pharmacology, pharmacokinetics and pharmacodynamics. Neurol Clin North Am 1992; 10: 487-509
35. Leon AS, Spiegel HE. The effect of an antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972; 12: 263-7
36. Malcolm SL, Allen JG, Bird H, et al. Single dose pharmacokinetics of Madopar HBS in patients and the effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987; 27: 28-35
37. Campbell NRC, Hasinoff B, Chernenko G, et al. The effect of ferrous sulfate and pH on L-dopa absorption. Can J Physiol Pharmacol 1990; 68: 603-7
38. Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989; 45: 220-5
39. Campbell NRC, Rankine D, Goodridge AE, et al. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30: 599-605
40. Berkowitz DM, McCallum RW. Interacticm of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980; 27: 415-20
41. Groden BM. Parkinsonism occurring with methyldopa treatment [letter]. BMJ 1963; 2: 1001
42. Peastin MJT. Parkinsonism associated with alpha-methyldopa therapy [letter]. BMJ 1964; 2: 168
43. Strang RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J 1966; 95: 928-9
44. Rosenblum AM, Montgomery EB. Exacerbation of parkinsonism by methyldopa. J Am Med 1980; 244: 2727-8
45. Gibberd FB, Small E. Interaction between levodopa and methyldopa. BMJ 1973; 2: 90-1
46. Shoulson I, Chase TN. Clonidine and the antiparkinsonian response to L-dopa or piribedil. Neuropharmacolouy 1976; 15: 25-7
47. Bianchine JR, Sunyapridakul L. Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease. Drugs 1973; 6: 364-88
48. Hunt-Fugate AK, Zander J, Lesar TS. Adverse reactions due to dopamine blockade by amoxapine. Pharmacotherapy 1984; 4: 35-9
49. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase inhibitor without the 'cheese effect'. Psychopharmacolopy 1978; 57: 33-8
50. Edwards M. Adverse interaction of levodopa with tricyclic antidepressanls. Practitioner 1982; 226: 1448-9
51. Morgan JP, Riviera-Calimlim L, Messiha F, et al. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975; 25: 1029-34
52. Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson's disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69-74
53. Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson's Disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69-74
54. Brion N, Kollenbach K, Marion MH, et al. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 1992; 15: 229-35
55. Mizuta E, Kuno S. Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease Clin Neuropharmacol 1943; 16: 448-50
56. Goldberg LI, Whitsett TL. Cardiovascular effects of levodopa. Clin Pharmacol Ther 1971; 12: 376-82
57. Kissel P, Tridon P, Andre JM. Levodopa-propranolol therapy in parkinsonian tremor [letter]. Lancet 1974; 1: 403-4
58. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, editors. The scientific basis for the treatment of Parkinson's disease. Park Ridge (NJ): Parthenon, 1992: 89-112
59. Carpentier AF, Bonnet AM, Vidailhet M, et al. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996; 46: 1548-51
60. Mendez JS, Cotzias GC, Mena I, et al. Diphenylhydantoin blocking of levodopa effects. Arch Neurol 1975; 32: 44-6
61. Kurth MC, Tetrud JW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's disease with severe fluctuations: a pilot study. Neurology 1993; 43: 1036-9
62. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993; 43: 1698-703
63. Pappert EJ, Goetz GC, Niederman F, et al. Liquid levodopa/ carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996; 47: 1493-5
64. Bennett Jr JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551-5
65. Birkmayer W, Riederer P, Youdim MBH, et al. The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303-26
66. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
67. Roberts J, Waller DG, O'Shea N, et al. The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. Br J Clin Pharmacol 1995; 40: 404-6
68. Schulzer M, Mak E, Calne DB. The antiparkinsonian effect of deprenyl derives lrom transient improvement that is likely to be symptomatic. Ann Neurol 1992; 32: 795-8
69. Insel TR, Roy BF, Cohen RM. Possible development of serotonin syndrome in man. Am J Psychiatry 1982; 139: 954-5
70. Suchowersky O, de Vries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990; 35: 571-2
71. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995; 45: 219-23
72. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction [letter]. Ann Pharmacother 1992; 26: 1300
73. Monastruc JL, Chamontin B, Senard JM, et al. Pseudopheochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341: 555
74. Waters CH. Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 1994; 21: 259-61
75. Janowsky EJ, Risch C, Janowsky DS. Effects of anesthesia on patients taking psychotropic drugs. J Clin Psychopharmachol 1981; 1: 14-20
76. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246
77. Richards GA, Fritz VU, Pincus P, et al. Unusual drug interactions between monamine oxidase inhibitors and tricyclic antidepressants. J Neurol Neurosurg Psychiatry 1987; 50: 1240-1
78. Tackley RM, Tregakis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anesthesia 1987; 42: 760-3
79. Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994; 25: 813-24
80. Keranen T, Gordin A, Harjla V-P, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16: 145-56
81. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994; 44: 2685-8
82. Tedroff J, Hartvig P, Bjurling P, et al. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm 1991; 85: 11-7
83. Guldberg HC, Marsden CD. Catechol-O-methyltransferase: pharmacological aspects and physiological role [letter]. Pharmacol Rev 1975; 27: 135-206
84. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. In: Narbayashi H, Nagatsu T, Yangisawa N, et al., editors. Advances in neurology. New York (NY): Raven Press, 1993: 703-6
85. Factor SA, Friedman JM. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12: 483-96
86. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993; 150: 169
87. Miller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988; II: 1500
88. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991; 52: 223-5
89. Grohmann R, Ruther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology 1989; 99 Suppl.: S101-4
90. Cobb CD, Anderson CB, Seidel DR. Possible interactions between clozapine and lorazepam. Am J Psychiatry 1991; 148: 1606-7
91. Syzmananski S, Lieberman JA, Picou D, et al. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991; 52: 21-2
92. Lemus CZ, Liberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry 1989; 11: 127-30
93. Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493-5
94. Wolters ECH, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-7
95. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter]. Lancet 1994; 344: 681
96. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-9
97. Korczyn AD, Goldberg GJ. Extrapyramidal effects of neuroleptics. J Neurol Neurosurg Psychiatry 1976; 39: 866-9
98. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results with levodopa. J Neurol Neurosurg Psychiatry 1988; 51: 850-4
99. Sempere AP, Duarte J, Cabezas C. Parkinsonism induced by amlodipine. Mov Disord 1995; 10: 115-6
100. de Mari M, De Blasi R, Lamberti P. Unilateral pallidal lesions after acute disulfiram intoxication: a clinical and magnetic resonance study. Mov Disord 1993; 8: 247-9
101. Lecamwasam D, Syneck B, Moyles K. Chronic lithium neurotoxicity presenting as Parkinson's disease: a cross-sectional study of patients with 15 years or more on lithium. Int Clin Psychopharmacology 1994; 9: 127-9
102. Ejima A, Imamura T, Nakamura S. Manganese intoxication during total parenteral nutrition [letter]. Lancet 1992; 339: 426
103. Olive JM, Masana L, Gonzalez J. Meperidine and reversible Parkinsonism. Mov Disord 1994; 9: 115-6
104. Teusink JP, Alexopoulos GS, Shamoian CA. Parkinsonian side effects induced by a monoamine oxidase inhibitor. Am J Psychiatry 1984; 141: 118-9
105. Ott BR, Lannon MC. Exacerbation of Parkinsonism by tacrine. Clin Neuropharmacol 1992; 15: 322-5
106. Alves RSC, Barbosa ER, Scaff M. Postvaccinal parkinsonism. Mov Disord 1992; 7: 178-80
107. Indo T, Ando K. Metoclopramide-induced parkinsonism. Arch Neurol 1982; 39: 494-6
108. Montagna P, Gabellini AS, Montari I, et al. Parkinsonian syndrome after long-term treatment with clebopride. Mov Disord 1992; 7: 89-90
109. Mena AM, de Yebenes MJG, Taberno C, et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995; 18: 410-26
110. Micheli F, Fernandez Pardel M, Gatto M, et al. Flunarizine and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 37: 881-4
111. Garcia-Albea E, Jimenez-Jimenez FJ, Ayuso-Peralta L, et al. Parkinsonism unmasked by verapamil. Clin Neuropharmacol 1993; 16: 263-5
112. Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989; 87: 95-6
113. Dotti M, Frederico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995; 10: 233-4
114. Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspective on its method of action. Am J Med 1986 Suppl. 3B: 1-9
115. LeWitt PA, Walters A, Hening W, et al. Persistent movement disorders induced by buspirone. Mov Disord 1993; 8: 331-4
116. Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonism in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16: 451-5
117. Shindler JS, Finnerty GT, Towlson K, et al. Domperidone and levodopa in Parkinson's disease. Br J Clin Pharmacol 1984; 18: 959-62
118. Cann PA, Read NW, Holdsworth CD. Galactorrhea as a side-effect of domperidone. BMJ 1983; 286: 1395-6
119. Friedman A, Sienkiewicz J. Psychotic complications of long term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991; 84: 111-3
120. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991; 12: 283-95
121. Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinso's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 47: 1305-8
122. Merli GJ, Bell RD. Preoperative management of the surgical patient with neurologic disease. Med Clin North Am 1987; 71 (3): 511
123. Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 425-43
124. Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and hallucinations in PD. Ann Intern Med 1989; 111: 218-22
125. Solomon D, Solomon D, Albin M. Neurologic syndromes and their disorders with their anesthetic implications. In: Albin MS, editor. Textbook of neuroanesthesia. New York (NY): McGraw Hill, 1997: 409-11
126. Mets B. Acute dystonia after alfentanil in untreated Parkinson's disease. Anesth Analg 1991; 72: 557-8
127. Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med 1990; 323: 1177-83
128. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995: 45; 219-23
129. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94-104
130. Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983-5
131. Lappin RI, Auchinloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 331: 1021-2